With more than 6000 patients using the injection-free insulin delivery device, CeQur Simplicity patch, Medtech company CeQur has secured fresh equity funding to further drive growth and accelerate commercial expansion efforts. This will see the company bring the solution to more healthcare providers and patients managing diabetes.
CeQur Simplicity patch is a discreet, injection-free bolus insulin delivery solution offering a convenient solution to individuals on multiple daily injections. One CeQur Simplicity patch holds up to 200 units of rapid-acting insulin administered in two-unit increments and replaces, on average, twelve daily mealtime injections over four days. Clinical research has shown that nearly 90% of patients using CeQur Simplicity reported following their insulin regimen better as compared to multiple daily injections. The Patch is clinically proven to improve glycemic control, with patients achieving significantly improved A1C and time-in-range (TIR) goals.
With Headquarters in Horw (Lucerne) and Greenville (US), CeQur has seen growing adoption of the CeQur Simplicity patch, with over 6,000 patients currently using the device. The company also continues to increase and improve pharmacy access. In addition to the more than two-thirds of commercially insured patients on formulary, CeQur has reached agreements with numerous Medicare Part-D and State Medicaid programs. Overall, better than 80% of all claims are being covered as a pharmacy benefit. The average copay is less than $45/month.
Using the funding from the latest equity financing round, CeQur plans to drive growth and accelerate commercial expansion efforts and support its outreach initiatives to bring CeQur Simplicity™ to more healthcare providers and patients managing diabetes. The company plans to further expand its sales force and clinical team.
“We are grateful for the support of our investors as we accelerate our mission to transform diabetes care,” said Brad Paddock, President and CEO of CeQur. “This financing will enable us to reach more patients, expand our commercial footprint, and continue innovating solutions that simplify mealtime insulin management”, said Mike Rubino, CFO of CeQur.
This round comes after the completion of all qualifications related to CeQur’s 40,000 sq/ft automated cleanroom manufacturing facility in Q4 2024. The facility is planned to start manufacturing the commercial product in 2025.
(Press release/RAN)
The new Swiss Venture Capital Report was published on 26 January. It analyses 304 financing rounds closed in 2020 and includes further article such as an interview with Michael Hengartner, President of the ETH Board, and a list of Swiss "soonicorns". 
Please login or sign up to comment.
Commenting guidelines